Literature DB >> 8047989

Portal vein administration of donor cells promotes peripheral allospecific hyporesponsiveness and graft tolerance.

S Yu1, Y Nakafusa, M W Flye.   

Abstract

BACKGROUND: Major histocompatibility complex-mismatched Lewis rate cardiac grafts (inferior vena cava drained) are promptly rejected by Buffalo recipients (mean survival time, 7 days). Ultraviolet-B (UVB) irradiation modulates donor immunogenicity and down-regulates in vitro immune responses. We found that Buffalo recipients (BUF; RT1b) preimmunized with 2.5 x 10(7) nontreated Lewis spleen cells (LEW; RT1(1)) by portal venous (PV) injection 7 days before a portal vein-drained heterotopic graft of LEW heart resulted in only 20% surviving long-term (n = 10) (naive rats rejected a cardiac allograft drained into the portal vein in mean survival time of 13.5 days [n = 5]). In contrast, BUF recipients receiving PV injection of UVB-treated LEW spleen cells permitted 70.6% indefinite allograft survival (n = 34) with a mean survival time of greater than 150 days.
METHODS: These studies examined the effect of untreated or UVB-irradiated donor spleen cells administered intraportally on the recipient's cell-mediated responsiveness as serially measured by the mixed lymphocyte culture and limiting dilution analysis of T-helper precursors (pTH) and cytotoxic precursors (pCTL). Survival of heterotopic cardiac allografts transplanted with PV drainage at various intervals after PV alloantigen administration were correlated with changes in these in vitro studies.
RESULTS: The precursor frequencies in the spleens of BUF recipients given nontreated LEW spleen cells intraportally 7 days previously were 1/16,170 (pTH) and 1/11,929 (pCTL), whereas those in the spleen of BUF recipients receiving UVB-treated LEW spleen cells decreased to 1/152,409 pTH and < 1/5 X 10(5) pCTL. These hyporesponsive BUF spleen cells responded normally to the third-party alloantigen, irradiated ACI spleen cells (RT1 alpha), with mixed lymphocyte culture tritiated incorporation of 133,220 cpm (control, 123,276 cpm), 1/13,364 pTH (control, 1/13,541), and 1/71,156 pCTL (control, 1/73,985), indicating that the hyporesponsiveness induced by UVB-treated donor spleen cells is antigen specific. The recovery of in vitro responsiveness correlates with decreasing cardiac graft survival to normal rejection times by 200 days after portal vein antigen administration. When 100 units/ml exogenous recombinant interleukin-2 (rIL-2), but not rIL-1 or rIL-4, was added to cultures, the hyporesponsiveness of spleen cells recovered to normal levels with tritiated incorporation of 201,227 cpm and pTH frequency of 1/32,227, suggesting that the hyporesponsiveness to donor antigen is due to anergized T-helper lymphocytes and not to clonal deletion.
CONCLUSIONS: By administering properly modified alloantigen into the hepatic environment by portal vein inoculation, prolonged T-cell anergy can be induced, which allows the indefinite acceptance of donor-specific heterotopic cardiac allografts.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8047989

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  11 in total

1.  Importance of gastrointestinal ingestion and macromolecular antigens in the vein for oral tolerance induction.

Authors:  Ayako Wakabayashi; Yoshihiro Kumagai; Eiji Watari; Masumi Shimizu; Masanori Utsuyama; Katsuiku Hirokawa; Hidemi Takahashi
Journal:  Immunology       Date:  2006-06-23       Impact factor: 7.397

Review 2.  Oral tolerance.

Authors:  Howard L Weiner; Andre Pires da Cunha; Francisco Quintana; Henry Wu
Journal:  Immunol Rev       Date:  2011-05       Impact factor: 12.988

Review 3.  Oral tolerance.

Authors:  Ana M C Faria; Howard L Weiner
Journal:  Immunol Rev       Date:  2005-08       Impact factor: 12.988

4.  Apoptosis within spontaneously accepted mouse liver allografts: evidence for deletion of cytotoxic T cells and implications for tolerance induction.

Authors:  S Qian; L Lu; F Fu; Y Li; W Li; T E Starzl; J J Fung; A W Thomson
Journal:  J Immunol       Date:  1997-05-15       Impact factor: 5.422

5.  Hepatic stellate cells function as regulatory bystanders.

Authors:  Shintaro Ichikawa; Daniel Mucida; Aaron J Tyznik; Mitchell Kronenberg; Hilde Cheroutre
Journal:  J Immunol       Date:  2011-04-01       Impact factor: 5.422

6.  Portal venous and enteric exocrine drainage versus systemic venous and bladder exocrine drainage of pancreas grafts: clinical outcome of 40 consecutive transplant recipients.

Authors:  M S Cattral; D L Bigam; A W Hemming; A Carpentier; P D Greig; E Wright; E Cole; D Donat; G F Lewis
Journal:  Ann Surg       Date:  2000-11       Impact factor: 12.969

7.  A critical role of TRAIL expressed on cotransplanted hepatic stellate cells in prevention of islet allograft rejection.

Authors:  Horng-Ren Yang; Ching-Chuan Hsieh; Lianfu Wang; John J Fung; Lina Lu; Shiguang Qian
Journal:  Microsurgery       Date:  2010-05       Impact factor: 2.425

8.  The activation state of human intrahepatic lymphocytes.

Authors:  Z Tu; A Bozorgzadeh; I N Crispe; M S Orloff
Journal:  Clin Exp Immunol       Date:  2007-05-18       Impact factor: 4.330

9.  Tissue-specific abundance of regulatory T cells correlates with CD8+ T cell dysfunction and chronic retrovirus loads.

Authors:  Lara Myers; Ronald J Messer; Aaron B Carmody; Kim J Hasenkrug
Journal:  J Immunol       Date:  2009-07-08       Impact factor: 5.422

10.  Human hepatic stellate cells inhibit T-cell response through B7-H1 pathway.

Authors:  Ronald Charles; Hong-Shiue Chou; Lianfu Wang; John J Fung; Lina Lu; Shiguang Qian
Journal:  Transplantation       Date:  2013-07-15       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.